CMTM5 and breast cancer: In addition to determining the mRNA expression levels of several CMTM family members, we herein used UALCAN and found that CMTM5 was significantly dysregulated in breast cancer relative to other CMTM family members (45.36-fold vs. 1.02–3.72-fold).